CHEMOIMMUNOTHERAPY FOR PROPHYLAXIS OF RECURRENCE IN SUPERFICIAL BLADDER-CANCER - INTERFERON-ALPHA-2B VERSUS INTERFERON-ALPHA-2B WITH EPIRUBICIN

被引:17
作者
FERRARI, P
CASTAGNETTI, G
POLLASTRI, CA
FERRARI, G
TAVONI, F
GRASSI, D
机构
[1] Department of Urology, University of Modena
关键词
EPIRUBICIN; INTERFERON-ALPHA-2B; INTRAVESICAL THERAPY; SUPERFICIAL BLADDER CANCER;
D O I
10.1097/00001813-199205000-00006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Eighty-five patients who had undergone transurethral resection (TUR) of superficial bladder cancer were randomized to one of two treatments. Patients in Group 1 received a 10-month course of intravesical therapy with interferon (IFN)-alpha-2b (50 MU dose), commencing 21 days after TUR once a week for 8 weeks, then once every 15 days for 4 months and then finally once a month for 4 months. Patients in Group 2 received epirubicin (80 mg) intravesically 0, 24 and 48 h after TUR, and then 21 days after TUR received IFN-alpha-2b as for Group 1. The results confirmed the efficacy of immunoprophylaxis with IFN-alpha-2b, and early treatment with epirubicin tended to further reduce the percentage of relapses and extended the disease-free interval.
引用
收藏
页码:25 / 27
页数:3
相关论文
共 11 条
[1]  
COON JS, 1982, AM J CLIN PATHOL, V77, P692
[2]   A RANDOMIZED CONTROLLED-STUDY OF INTRAVESICAL INTERFERON-ALPHA-2B IN CARCINOMA INSITU OF THE BLADDER [J].
GLASHAN, RW .
JOURNAL OF UROLOGY, 1990, 144 (03) :658-661
[3]  
KOVARIK S, 1968, ARCH PATHOL, V86, P12
[4]  
LIMAS C, 1979, CANCER, V44, P2099, DOI 10.1002/1097-0142(197912)44:6<2099::AID-CNCR2820440621>3.0.CO
[5]  
2-I
[6]  
RICHIE JP, 1989, CANCER PRINCIPLES PR, P1008
[7]  
SADOUGHI N, 1982, UROLOGY, V20, P143, DOI 10.1016/0090-4295(82)90344-2
[8]  
SHORTLIFFE L D, 1984, Journal of Urology, V131, p171A
[9]   BLOOD-GROUP ANTIGENS AND BLADDER-CARCINOMA - A PERSPECTIVE [J].
STEIN, BS ;
KENDALL, AR .
UROLOGY, 1982, 20 (03) :229-233
[10]   THE BIOLOGY AND TREATMENT OF SUPERFICIAL BLADDER-CANCER [J].
TORTI, FM ;
LUM, BL .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (05) :505-531